Interactions between Elvitegravir and Multiple Trace Element

The copper sulfate and manganese sulfate in Multiple Trace Element both have a moderate potential interaction with Biliary Obstruction.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

Elvitegravir has a major potential interaction with Liver Disease.

The use of elvitegravir is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). No dosage adjustment is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.

The copper sulfate and manganese sulfate in Multiple Trace Element both have a moderate potential interaction with Liver Disease.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

The chromic chloride hexahydrate, copper sulfate, manganese sulfate and zinc sulfate in Multiple Trace Element all have a moderate potential interaction with Malabsorption Syndrome.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

Elvitegravir has a major potential interaction with Renal Dysfunction.

The use of elvitegravir is not recommended in patients with severe renal impairment (estimated creatinine clearance below 30 mL per minute). No dosage adjustment is recommended in patients with estimated creatinine clearance greater than or equal to 30 mL per minute.

The manganese sulfate in Multiple Trace Element has a moderate potential interaction with Renal Dysfunction.

Manganese sulfate and manganese chloride preparations contain aluminum and may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum. Patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Caution is advised in patients with renal impairment, particularly in premature or neonates patients.

The chromic chloride hexahydrate and zinc sulfate in Multiple Trace Element both have a moderate potential interaction with Renal Dysfunction.

The trace metals, chromium and zinc, are excreted primarily in the urine. Selenium is partially excreted in the urine. Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.